# Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

> **NCT01744249** · PHASE2,PHASE3 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 256 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Advanced Cancer

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Sandostatin LAR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01744249
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744249, "Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01744249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*